This is a working overview of counterion content, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-11-15. Anything still debated is marked as such rather than presented as settled.
The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.
Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.
Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue. Its sequence, Aib-His-D-2-Nal-D-Phe-Lys-NH2, combines three non-proteinogenic residues with a C-terminal amide. The N-terminal aminoisobutyric acid unit and the two aromatic D-amino acids distinguish it from peptides assembled only from standard L-amino acids. Its formula is C38H49N9O5, corresponding to an average mass near 711.9 Da. At neutral pH the molecule carries a net positive charge, a property that shapes its behaviour in chromatographic and electrophoretic systems.
Common solvents for laboratory work include water, buffered saline, and dimethyl sulfoxide. Once dissolved, the peptide is exposed to hydrolysis and oxidation, and alkaline conditions accelerate breakdown. Low-binding plasticware and the addition of a carrier protein reduce losses to container surfaces, which can otherwise be substantial at low concentrations. Solutions are typically kept cold and used within days. Investigators working with the compound generally prepare fresh working dilutions rather than storing dilute stocks, and they avoid repeated warming of the same vial.
Reversed-phase high-performance liquid chromatography is the standard method for purity assessment, most often on a C18 column with a water and acetonitrile gradient and trifluoroacetic acid or formic acid as an ion-pairing agent. Mass spectrometry by electrospray or matrix-assisted laser desorption confirms the expected mass and reveals truncated or modified sequences. Amino acid analysis and sequencing provide orthogonal structural evidence. Typical impurities include deletion sequences, oxidized products, and dimeric species. Detection wavelength, usually 214 or 220 nanometers, should be reported because response factors differ between peptides.
Purity is normally reported as a percentage of total peak area, a figure that does not account for water content, residual solvents, or counterions. Trifluoroacetate and acetate are the most frequent counterions in lyophilized peptides, and they shift the true peptide content away from the mass of the powder. A separate quantitative assay is therefore needed to state content accurately. Certificates of analysis often omit these details, which makes batch-to-batch comparison difficult and limits conclusions drawn when results from different suppliers are compared.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Pentapeptide with C-terminal amide |
| Average mass | Approximately 711.9 Da | Value derived from the formula |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water and aqueous acetonitrile | Dissolution aided by acidic diluents |
| Common synonyms | Ipamorelin; NNC 26-0161 | Code name used in early reports |
Lyophilized material is generally stored cold and dry, with desiccant, and protected from light. In solution the peptide is more vulnerable: the histidine side chain can oxidize, and repeated freeze-thaw cycles promote aggregation and loss of material to container surfaces. A mildly acidic aqueous buffer is often used for short-term handling because it limits several degradation routes. Accurate prediction of long-term stability under a given set of conditions is difficult, and published stability data remain sparse.
Published discussion of this compound is uneven. Some references describe it as a tool for probing growth hormone regulation, while others focus on analytical characterization or on comparisons with related secretagogues. Statements about selectivity, half-life and potency often trace back to a small number of original reports that later authors cite secondhand. Readers evaluating a claim should therefore check whether a figure reflects a direct measurement or a repeated citation, and whether the underlying study was conducted in animals, in isolated cells or in human volunteers.
Identity and purity assessment for a research peptide of this kind typically combines reversed-phase high-performance liquid chromatography with mass spectrometry. The chromatographic run separates related impurities and yields a purity percentage, while electrospray ionization or matrix-assisted laser desorption mass spectrometry confirms the expected molecular mass. Amino acid analysis or tandem mass spectrometry sequencing can add confidence when material is intended for quantitative work. Laboratories differ in how they calculate and report purity, so figures from different sources are not always directly comparable.
Most published work on ipamorelin comes from rodent studies and small early-phase human trials. Subcutaneous and intravenous routes have been used, while oral delivery is limited by poor absorption and rapid breakdown in the gut. The reported plasma half-life is short, on the order of two hours, and varies with species and assay method. Whether chronic use produces meaningful clinical benefit remains unresolved, and long-term safety data in humans are sparse. No major regulatory agency has approved the compound as a therapeutic drug.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues that resist enzymatic breakdown. Researchers at Novo Nordisk described the compound in the 1990s while searching for agents that release growth hormone with fewer side effects than earlier secretagogues. The molecule acts as an agonist at the ghrelin receptor, also called GHS-R1a, which is expressed in the pituitary and in several peripheral tissues.
Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.
Storage recommendations for the dry solid center on low temperature and low moisture, most often -20 °C in a sealed, desiccated container protected from light. Solutions are less stable than the powder and are usually kept cold and used within a short window. Freeze-thaw cycling is a recognized source of loss, and aliquoting before freezing is a standard precaution. These practices derive from general peptide handling principles rather than from a single published stability trial, so exact shelf lives should be treated as approximate.
Analytical confirmation relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry for identity and purity assessment. Mass spectrometry distinguishes the intact molecule from truncation products and from oxidation or deamidation variants that share similar chromatographic retention. Immunoassays appear in some biological studies but can cross-react with related peptides, so they are weaker tools for identity work. Reported purity figures depend heavily on the gradient, detector, and integration method used, which complicates direct comparison between laboratories.
William said in 1985, "We all love The Shangri-Las, and one day we're going to make Shangri-Las records." Jim mentioned his liking for Pink Floyd, Siouxsie and the Banshees, The Monkees, and Muddy Waters. Early demos displayed a similarity to the Ramones, prompting the brothers to add another element to their sound; in William's words: "That's why we started using noise and feedback. We want to make records that sound different." They began playing live in early 1984. In the early days William Reid's guitar would be left out of tune, while Dalglish's drum kit was limited to two drums, and Hart's bass guitar only had three strings, down to two by 1985; in Hart's words, "That's the two I use. I mean what's the fucking point spending money on another two? Two is enough." Struggling to get gigs, the band took to turning up at venues claiming to be the support band, playing their short set and making a quick exit. After failing to generate any interest from concert promoters and record labels in Scotland, the band relocated to Fulham, London, in May 1984, and soon afterwards their demo tape was passed to fellow Scot Alan McGee by Bobby Gillespie. Subsequently, McGee promoted a gig for the band at the Living Room in London in June 1984. On the strength of hearing the band sound check, McGee signed them to his Creation Records label on a one-off deal, and McGee also became the band's manager. Their debut single, "Upside Down", was recorded in October and released in November that year.
== Alternative for specimen transport == One common alternative to dry shippers is using dry ice. This method reduces package weight and costs since there's no need for return shipping, unlike with dry shippers. However, at -80 °C (176 °F), dry ice might not provide a temperature low enough for all specimens. For instance, while cryopreserved mouse spermatozoa can handle this temperature for short periods without losing their fertilization capacity, cryopreserved mouse embryos require colder environments, such as those below -150 °C (302 °F) in dry shippers, to maintain their quality. Another method is shipping freeze-dried samples at ambient temperatures, as seen with freeze-dried mouse spermatozoa. This can be more cost-effective, but many samples, when freeze-dried, experience a notable decline in quality, limiting its applicability.
At this point, it was known that organic molecules could be formed from inorganic starting materials, as Friedrich Wöhler had described the Wöhler synthesis of urea from ammonium cyanate in 1828. Several other early seminal works in the field of organic synthesis followed, including Alexander Butlerov's synthesis of sugars from formaldehyde and Adolph Strecker's synthesis of the amino acid alanine from acetaldehyde, ammonia, and hydrogen cyanide. In 1913, Walther Löb synthesized amino acids by exposing formamide to silent electric discharge, so scientists were beginning to produce the building blocks of life from simpler molecules, but these were not intended to simulate any prebiotic scheme or even considered relevant to origin of life questions. But the scientific literature of the early 20th century contained speculations on the origin of life. In 1903, physicist Svante Arrhenius hypothesized that the first microscopic forms of life, driven by the radiation pressure of stars, could have arrived on Earth from space in the panspermia hypothesis. In the 1920s, Leonard Troland wrote about a primordial enzyme that could have formed by chance in the primitive ocean and catalyzed reactions, and Hermann J. Muller suggested that the formation of a gene with catalytic and autoreplicative properties could have set evolution in motion. Around the same time, Alexander Oparin's and J. B. S.
Sources: en.wikipedia.org
== Measurement == Further information: Thyroid function tests Triiodothyronine (T3) and thyroxine (T4) can be measured as free T3 and free T4, which are indicators of their activities in the body. They can also be measured as total T3 and total T4, which depend on the amount that is bound to thyroxine-binding globulin (TBG). A related parameter is the free thyroxine index, which is total T4 multiplied by thyroid hormone uptake, which, in turn, is a measure of the unbound TBG. Additionally, thyroid disorders can be detected prenatally using advanced imaging techniques and testing fetal hormone levels.
MALS is most commonly used for the characterization of mass and size of molecules in solution. Early implementations of MALS such as those discussed by Bruno H. Zimm in his paper "Apparatus and Methods for Measurement and Interpretation of the Angular Variation of Light Scattering; Preliminary Results on Polystyrene Solutions" involved using a single detector rotated about a sample contained within a transparent vessel. MALS measurements from non-flowing samples such as this are commonly referred to as "batch measurements". By creating samples at several known low concentrations and detecting scattered light about the sample at varying angles, one can create a Zimm plot by plotting :
The synthesis of an mRNA display library starts from the synthesis of a DNA library. A DNA library for any protein or small peptide of interest can be synthesized by solid-phase synthesis followed by PCR amplification. Usually, each member of this DNA library has a T7 RNA polymerase transcription site and a ribosomal binding site at the 5' end. The T7 promoter region allows large-scale in vitro T7 transcription to transcribe the DNA library into an mRNA library, which provides templates for the in vitro translation reaction later. The ribosomal binding site in the 5'-untranslated region (5' UTR) is designed according to the in vitro translation system to be used. There are two popular commercially available in vitro translation systems. One is E. coli S30 Extract System (Promega) that requires a Shine-Dalgarno sequence in the 5' UTR as a ribosomal binding site; the other one is Red Nova Lysate (Novagen), which needs a ΔTMV ribosomal binding site. Once the mRNA library is generated, it will be Urea-PAGE purified and ligated using T4 DNA ligase to the DNA spacer linker containing puromycin at the 3' end. In this ligation step, a piece of mRNA is ligated with a single stranded DNA with the help from T4 DNA ligase. This is not a standard T4 DNA ligase ligation reaction, where two pieces of double stranded DNA are ligated together. To increase the yield of this special ligation, a single stranded DNA splint may be used to aid the ligation reaction.
Some of the noradrenergic pathways in the central nervous system form part of the ascending reticular activating system, which promotes arousal when stimulated. Prazosin inhibits the output neurons of the noradrenergic pathways in that system, in turn causing sedation. The drug is usually recommended for severe stings from the Indian red scorpion.
Sources: en.wikipedia.org
It is a synthetic five-amino-acid peptide that acts as a growth hormone secretagogue. Three of its residues are non-standard amino acids, and the chain ends in an amide rather than a free acid. The molecule is small enough that it can be characterised by routine peptide analytical techniques.
It has not received marketing approval as a medicine in the United States or the European Union. Supplied material is generally described and handled as a research chemical. Regulatory treatment varies by jurisdiction, and some countries restrict growth hormone secretagogues under sports or medicines legislation.
Earlier secretagogues were associated with broader hormonal responses, including measurable changes in cortisol and prolactin. Reports on this peptide describe a narrower profile in which growth hormone release is the most prominent effect. The observation is influential because it shapes how the compound is compared with other members of the same receptor family.
It is reported as the percentage of total peak area in a reversed-phase chromatogram. That number does not reflect water content, residual solvents, or counterions. The actual peptide content is therefore lower than the stated purity figure suggests.